Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
相关临床试验
9
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
已完成
4
44.4%
招募中
1
11.1%
终止
4
44.4%
暂无批准数据
- GSK has agreed to acquire RAPT Therapeutics for $2.2 billion to gain control of ozureprubart, a potentially best-in-class anti-IgE antibody for food allergy protection. - Ozureprubart offers potential for less frequent dosing every 12 weeks compared to current standard-of-care therapy requiring injections every 2-4 weeks. - The acquisition addresses significant unmet medical need, with over 17 million people diagnosed with food allergies in the US and more than 1.3 million suffering severe reactions. - Phase IIb trial results are expected in 2027, with phase III trials planned for both adult and pediatric populations.
- RAPT Therapeutics' experimental drug RPT904 demonstrated comparable efficacy and safety to Roche and Novartis' Xolair in treating chronic spontaneous urticaria in a 137-patient mid-stage trial conducted in China. - Nearly 46% of patients receiving RPT904 achieved complete symptom resolution at week 16, compared to 33.3% of patients treated with Xolair. - The study tested RPT904 administered at 8-week and 12-week intervals versus Xolair's standard 4-week dosing schedule, potentially offering a more convenient treatment option. - RAPT Therapeutics shares surged up to 90% following the positive trial results, reflecting investor confidence in the drug's commercial potential.
- RAPT Therapeutics will report topline data from a Phase 2 clinical trial of RPT904 in chronic spontaneous urticaria patients on October 20, 2025. - The trial was conducted by RAPT's partner Shanghai Jeyou Pharmaceutical Co., Ltd., with results to be presented in a premarket press release and webcast. - RPT904 represents a novel immunology-based therapy designed to modulate critical immune responses underlying inflammatory and immunological diseases. - The data release marks a significant milestone for RAPT's clinical-stage biopharmaceutical pipeline focused on addressing unmet needs in inflammatory conditions.
- RAPT Therapeutics received FDA clearance for its IND application to initiate a Phase 2b clinical trial of RPT904, a next-generation anti-IgE monoclonal antibody for food allergy treatment. - The prestIgE trial will evaluate RPT904's safety and efficacy in approximately 100 participants with food allergies to peanut, milk, egg, walnut, or cashew over 24-48 weeks. - RPT904 is designed as a half-life extended bio-better version of omalizumab, targeting the same epitope but with improved pharmacokinetic properties. - The company plans to initiate the Phase 2b trial by the end of 2025, advancing toward a potential best-in-class therapeutic option for the underserved food allergy community.
- DelveInsight's 2025 pipeline report reveals over 200 companies developing 220+ therapeutic candidates for gastric cancer treatment across all clinical stages. - Recent clinical developments include Bold Therapeutics' Phase 1b/2a study of BOLD-100 with FOLFOX chemotherapy and Jazz Pharmaceuticals' zanidatamab combination trials. - Leading pipeline candidates include tislelizumab (BeiGene), catumaxomab (Linton Pharm), and tivumecirnon (RAPT Therapeutics) targeting various mechanisms from PD-1 inhibition to regulatory T cell migration. - The pipeline encompasses diverse therapeutic approaches including monoclonal antibodies, small molecules, and combination therapies targeting novel mechanisms like Claudin 18.2 and DKK1 signaling.
• Phase I/II trial demonstrates 60% objective response rate for Tivumecirnon plus Keytruda in EBV-positive gastric cancer patients, including complete and partial responses. • The combination therapy showed manageable safety profile with median progression-free survival of 10.4 months and median duration of response of 17.3 months in EBV-positive patients. • Hanmi Pharmaceutical's oral CCR4 antagonist Tivumecirnon, developed in collaboration with RAPT Therapeutics and MSD, represents a potential breakthrough in cancer immunotherapy.
- DelveInsight's comprehensive analysis identifies over 70 pharmaceutical companies actively developing 75+ pipeline drugs for advanced cervical cancer treatment. - AstraZeneca's Imfinzi (durvalumab) leads late-stage developments, currently in Phase III trials for locally advanced cervical cancer, building on its success in lung cancer treatment. - Key clinical trials include promising immunotherapy combinations, with Merck's pembrolizumab plus chemoradiotherapy and AstraZeneca's volrustomig studies scheduled for significant developments in 2025.
• RAPT Therapeutics has commenced a Phase 2a clinical trial to assess RPT193, an oral, once-daily monotherapy, for treating moderate-to-severe asthma. • The trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of RPT193 over 14 weeks. • RPT193 selectively inhibits the migration of Th2 cells into inflamed tissues by blocking CCR4, making it a potential therapeutic option for Type 2-high asthma. • The primary endpoint is the proportion of patients who experience a loss of asthma control during the trial, with ICS and LABA being gradually tapered.
• RAPT Therapeutics secures exclusive worldwide rights, excluding China, to develop and commercialize RPT904, a long-acting anti-IgE antibody. • Shanghai Jemincare Pharmaceutical will receive $35 million upfront, potential milestone payments up to $672.5 million, and royalties on future sales. • RAPT plans to initiate a Phase 2b clinical trial of RPT904 in food allergy in the second half of 2025, addressing a significant unmet need. • Jemincare is currently conducting Phase 2 trials in China for asthma and chronic spontaneous urticaria, with topline data expected in 2025 and 2026.
• RAPT Therapeutics halts the development of zelnecirnon (RPT193) after receiving feedback from the FDA regarding safety concerns. • The decision follows a clinical hold placed on Phase 2 trials for asthma and atopic dermatitis due to a severe liver injury in one patient. • RAPT plans to advance next-generation CCR4 compounds with improved safety profiles and explore licensing opportunities for clinical-stage assets. • The company aims to identify a new candidate for inflammatory diseases in the first half of 2025, focusing on safer oral therapeutics.
